OneSpan (OSPN) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
31 Oct, 2026Executive summary
FY23 revenue rose 7% to $235.1M; subscription revenue grew 19% to $106.4M and ARR increased 11% to $154.6M.
Adjusted EBITDA rose 88% to $12.0M for FY23; Q4 Adjusted EBITDA was $11.2M, with GAAP operating income of $1.8M.
2024 priorities: efficient revenue growth, profitability and cash flow.
Financial highlights
Q4 revenue grew 11% YoY to $62.9M; FY23 revenue was $235.1M versus $219M in FY22.
Q4 gross profit was $43.5M at 69% margin; FY gross profit was $157.7M at 67% margin.
FY23 GAAP net loss was $29.8M versus $14.4M in FY22; operating loss widened to $28.9M from $27.1M.
FY23 Adjusted EBITDA was $12.0M versus $6.4M; Q4 was $11.2M versus $3.2M.
Outlook and guidance
FY24 guidance: revenue of $238M–$246M, ARR of $160M–$168M and Adjusted EBITDA of $47M–$52M.
Most cost-savings actions are expected to be completed by end-2024, reaching $64M–$65M in cumulative annualized savings; low-single-digit-million additional savings are expected in 2025.
Latest events from OneSpan
- Q3 revenue rose 12% as subscription growth drove higher FY 2026 guidance.OSPN
Q3 2026 - Q2 2026 revenue up 1%, subscription up 11%, Digital Agreements up 25%, and guidance raised.OSPN
Q2 2026 - All proposals, including director elections and stock plan amendments, passed with strong support.OSPN
AGM 2026 - Stockholders are encouraged to support all director nominees, including Mr. McConnell, at the 2026 meeting.OSPN
Proxy filing - Q1 2026 revenue up 4% to $66M, ARR up 14% to $192.1M, and full-year ARR guidance raised.OSPN
Q1 2026 - Annual meeting covers director elections, pay, equity plan, and auditor ratification, with strong governance.OSPN
Proxy filing - ARR up 11.5% to $187M, with software growth and strong cash flow driving profitability.OSPN
Q4 2025 - Q3 2025 saw 1% revenue growth, strong ARR, and robust capital returns amid revised guidance.OSPN
Q3 2025 - Profitability surged on subscription growth and cost controls, with guidance raised for Adjusted EBITDA.OSPN
Q3 2024